1stOncology™: Cancer Intelligence Service – Page 13824 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

AbbVie to Host Fourth-Quarter and Full-Year 2018 Earnings Conference Call

On January 3, 2019 AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, reported that it will announce its fourth-quarter and full-year 2018 financial results on Friday, January 25, 2019 before the market open (Press release, AbbVie, JAN 3, 2019, View Source [SID1234532409]). AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern). It will be accessible through AbbVie’s Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Actinium Pharmaceuticals, Inc. to Present at the 2019 Biotech Showcase™ in San Francisco

On January 3, 2019 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) reported that Sandesh Seth, Actinium’s Chairman and Chief Executive Officer will present at the Biotech Showcase 2019 being held on January 7-9 (Press release, Actinium Pharmaceuticals, JAN 3, 2019, View Source [SID1234532408]). The conference will be held at the Hilton San Francisco Union Square. Details of Actinium’s presentation are as follows:

Date: Monday, January 7, 2019
Time: 10:00 AM PT
Track: Yosemite A (Ballroom Level)
Venue: Hilton San Francisco Union Square

Members of Actinium’s Executive and Corporate Development teams will be available for 1-on-1 meetings during the conference. Those interested in scheduling a meeting with Actinium may do so by contacting Steve O’Loughlin, Actinium’s Principal Financial Officer via email to [email protected].

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.

Ophthotech Corporation to Present at the 37th Annual J.P. Morgan Healthcare Conference

On January 3, 2019 Ophthotech Corporation (NASDAQ: OPHT) reported that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 10, 2019 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) (Press release, Ophthotech, JAN 3, 2019, View Source [SID1234532407]).

Investors and the general public are invited to listen to a live webcast of the presentation at www.ophthotech.com. Please connect to Ophthotech’s website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. A replay will be available for 14 days following the presentation.

Allergan to Report Fourth Quarter and Full Year 2018 Earnings and Host Conference Call and Webcast

On January 3, 2019 Allergan plc (NYSE: AGN) reported it intends to release fourth quarter and full year 2018 financial results on Tuesday, January 29, 2019, prior to the open of U.S. Financial Markets (Press release, Allergan, JAN 3, 2019, View Source(3) [SID1234532406]).

Allergan will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, January 29, 2019 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the conference ID is 8599848.

A replay of the conference call will also be available beginning approximately two hours after the call’s conclusion and will remain available through 11:30 p.m. Eastern Time on February 28, 2019. The replay may be accessed by dialing (855) 859-2056 or (404) 537-3406 and entering the conference ID 8599848.

To access the webcast, please visit Allergan’s Investor Relations website at View Source;. A replay of the webcast will also be available on Allergan’s Investor Relations website.

Moleculin Announces Positive Data for its Pancreatic Cancer Drug Candidate

On January 3, 2019 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, reported that in preliminary animal studies, a second of its lead drugs, WP1732, has demonstrated enhanced activity in combination with checkpoint blockade antibodies in pancreatic cancer (Press release, Moleculin, JAN 3, 2019, View Source [SID1234532405]).

"After our sponsored research demonstrated that WP1066 was able to enhance immune checkpoint activity in a pancreatic cancer animal model," commented Walter Klemp, Moleculin’s Chairman and CEO, "we were optimistic that we could show similar potential results in our water soluble, WP1732 drug candidate. This is significant for several reasons. It shows that this is a consistent capability across our platform of STAT3 inhibitors and it further supports independent research suggesting that STAT3 may be a key to enabling checkpoint blockade activity in otherwise resistant tumors. Importantly, though, when you couple this with our recent findings that WP1732 accumulates disproportionately in the pancreas, we believe it points to WP1732 as a potentially pivotal new approach to treating pancreatic cancer. Expansion of the WP1732 and WP1066 in vivo studies is in progress."